Lecanemab for Treatment of Individuals with Early Alzheimer’s Disease (AD): Results in Apolipoprotein E ε4 (ApoE ε4) Non-carriers or Heterozygotes
Froelich et al
Lecanemab for Treatment of Individuals with Early Alzheimer’s Disease (AD): Results in Apolipoprotein E ε4 (ApoE ε4) Non-carriers or Heterozygotes
